Durable OS benefit of nivolumab plus ipilimumab versus chemotherapy was also observed in patients with non-squamous (median [95% CI] OS: 58.3 [20.4–NR] vs 26.4 [20.4–33.4] months) or squamous (median [95% CI] OS: 29.1 [14.6–48.8] vs 9.2 [5.3–41.1] months) histology, regardless of tumor PD-L1 expression; however, sample sizes were small in the squamous subgroup (Supplementary Table 1). The gene discussed is CD274; the disease is neoplasm.